Premium
TNF Pharmaceuticals Inc (TNFA)
NASDAQ
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Fully funded study to evaluate Wegovy and Ozempic patients at risk for increased inflammation associated with sarcopenic muscle deterioration Collaboration partner to use AI and machine learning...
Based on successful Phase 2a data, Company set to initiate Phase 2b sarcopenia study in early 2025; currently securing centers of excellence to begin enrollment First oral TNF-α inhibitor, if...
Prevail Partners, LLC investment priced at more than a 40% premium to market Prevail InfoWorks, Inc. to act as Clinical Research Organization partner; global full service CRO with hundreds of...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.16 | 13.1147540984 | 1.22 | 1.5799 | 1.05 | 266768 | 1.36734364 | CS |
| 4 | 0.113 | 8.91870560379 | 1.267 | 1.64 | 1.05 | 238807 | 1.404988 | CS |
| 12 | -0.31 | -18.3431952663 | 1.69 | 1.95 | 1.05 | 101410 | 1.43789067 | CS |
| 26 | -0.62 | -31 | 2 | 2.16 | 1.05 | 78051 | 1.54282014 | CS |
| 52 | -0.62 | -31 | 2 | 2.16 | 1.05 | 78051 | 1.54282014 | CS |
| 156 | -0.62 | -31 | 2 | 2.16 | 1.05 | 78051 | 1.54282014 | CS |
| 260 | -0.62 | -31 | 2 | 2.16 | 1.05 | 78051 | 1.54282014 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
